PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107. A total of 85 filers reported holding PHATHOM PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $871,733 | +46.7% | 84,063 | +102.6% | 0.00% | +100.0% |
| Q2 2023 | $594,280 | +186.0% | 41,500 | +42.6% | 0.00% | 0.0% |
| Q1 2023 | $207,774 | -30.3% | 29,100 | -17.6% | 0.00% | 0.0% |
| Q2 2022 | $298,000 | -45.5% | 35,304 | -12.2% | 0.00% | -50.0% |
| Q1 2022 | $547,000 | -56.4% | 40,216 | -37.0% | 0.00% | -33.3% |
| Q4 2021 | $1,255,000 | +73.3% | 63,796 | +182.8% | 0.00% | +50.0% |
| Q3 2021 | $724,000 | -46.5% | 22,555 | -43.6% | 0.00% | -33.3% |
| Q2 2021 | $1,353,000 | -34.1% | 39,984 | -26.8% | 0.00% | -40.0% |
| Q1 2021 | $2,053,000 | – | 54,655 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 3,760,869 | $39,000,212 | 12.45% |
| Frazier Life Sciences Management, L.P. | 10,109,279 | $104,833,223 | 6.96% |
| Decheng Capital Management III (Cayman), LLC | 850,000 | $8,814,500 | 2.94% |
| Carlyle Group Inc. | 3,496,808 | $36,191,963 | 1.57% |
| Ghost Tree Capital, LLC | 395,000 | $4,096,150 | 1.35% |
| Newtyn Management, LLC | 500,000 | $5,185,000 | 1.28% |
| Altium Capital Management LP | 220,000 | $2,281,400 | 1.19% |
| StepStone Group LP | 422,085 | $4,377,021 | 0.98% |
| MPM BioImpact LLC | 347,332 | $3,601,833 | 0.96% |
| NEA Management Company, LLC | 1,276,595 | $12,238,290 | 0.94% |